预约演示
更新于：2025-05-16
Mesalamine
美沙拉嗪
更新于：2025-05-16
概要
基本信息
原研机构 |
最高研发阶段批准上市 |
首次获批日期 瑞士 (1984-01-01), |
最高研发阶段(中国)批准上市 |
特殊审评孤儿药 (美国)、孤儿药 (日本) |
登录后查看时间轴
结构/序列
分子式C7H7NO3 |
InChIKeyKBOPZPXVLCULAV-UHFFFAOYSA-N |
CAS号89-57-6 |
关联
338
项与 美沙拉嗪 相关的临床试验CTR20250742
美沙拉秦肠溶片生物等效性试验
NCT06878495
Optimizing IBD Management: a Comparative Study on the Efficacy and Safety of 5-ASA De-escalation in Patients with Ulcerative Colitis and Crohn's Disease on Stable Biologic or Immunomodulator Therapy
ChiCTR2500098522
Clinical study of mesalazine with probiotics to improve senile UC
100 项与 美沙拉嗪 相关的临床结果
登录后查看更多信息
100 项与 美沙拉嗪 相关的转化医学
登录后查看更多信息
100 项与 美沙拉嗪 相关的专利（医药）
登录后查看更多信息
9,434
项与 美沙拉嗪 相关的文献（医药）2025-12-31ANNALS OF MEDICINE
Sodium butyrate alleviates DSS-induced inflammatory bowel disease by inhibiting ferroptosis and modulating ERK/STAT3 signaling and intestinal flora
Article
作者: Liu, Lulin ; Sun, Suxia ; He, Huaxing ; Chen, Nachuan ; Liu, Yingyin
BACKGROUND:
Inflammatory bowel disease (IBD), encompassing Crohn's disease (CD) and ulcerative colitis (UC), can seriously impact patients' quality of life. Sodium butyrate (NaB), a product of dietary fiber fermentation, has been shown to alleviate IBD symptoms. Some studies have shown that it is related to ferroptosis. However, the precise mechanism linking NaB, IBD, and ferroptosis is not clear.
OBJECTIVE:
This study aimed to demonstrate that NaB suppresses ferroptosis, thereby alleviating inflammatory bowel disease (IBD) through modulation of the extracellular regulated protein kinases/signal transducer and activator of transcription 3 (ERK/STAT3) signaling pathway and intestinal flora.
METHODS:
An IBD model was established using 2.5% (w/v) dextran sulfate sodium (DSS). Mice were orally administered low-dose NaB, high-dose NaB , or 5-aminosalicylic acid (5-ASA). Ferroptosis-related molecules were measured using specific kits, and western blotting (WB) and real-time polymerase chain reaction (RT-qPCR) were used to determine the levels of the target molecules.
RESULTS:
NaB alleviated symptoms in IBD mice, including reduced weight loss, prolonged colon length, reduced disease activity index (DAI), and reduced spleen index and mRNA expression of inflammatory factors. Additionally, NaB reduced the content of Fe2+ and myeloperoxidase (MPO) and increased the content of GSH and the activity of superoxide dismutase (SOD), which reflected NaB-inhibited ferroptosis. Moreover, western blotting showed that NaB enhanced STAT3 and ERK phosphorylation. In addition, NaB regulates the composition and functions of flora related to IBD.
CONCLUSION:
NaB alleviates IBD by inhibiting ferroptosis and modulating ERK/STAT3 signaling and the intestinal flora.
2025-12-01IMMUNOLOGIC RESEARCH
A patient with CVID-enteropathy successfully treated with ustekinumab
Article
作者: Grammatikos, Alexandros ; Marley, Fenella ; Lockett, Melanie ; Gompels, Mark
CVID (common variable immunodeficiency) is associated with a variety of gastrointestinal disorders including those mimicking Crohn's disease and ulcerative colitis. At present there is no clear trial data for the treatment of CVID enteropathy. There are no specific recommendations for treatment; however, it is commonly treated in a similar manner to inflammatory bowel disease, with corticosteroids, 5-aminosalicylates (5-ASA), azathioprine and anti-TNF therapy all being used. We describe the case of a 54-year-old with CVID-enteropathy presenting with diarrhoea and evidence of granulomatous inflammation on colonic biopsies. He was successfully treated with ustekinumab following failure/intolerance of prednisolone, 5-ASA and azathioprine. Features of CVID-enteropathy improved both clinically and histologically, with no evidence of serious treatment-related side effects.
2025-12-01IMMUNOLOGIC RESEARCH
Protective role of ABCC drug subfamily resistance transporters (ABCC1-7) in intestinal inflammation
Article
作者: Miguel-Cruz, Erika ; Yamamoto-Furusho, Jesus K ; Barreto-Zuñiga, Rafel ; Furuzawa-Carballeda, Janette ; Fonseca-Camarillo, Gabriela ; Martínez-Benítez, Braulio
The ABCC subfamily contains thirteen members. Nine of these transporters are called multidrug resistance proteins (MRPs). The MRPs have been associated with developing ulcerative colitis (UC). This study aimed to evaluate the ABCC expression in UC patients and its role in a dextran sulfate sodium (DSS)-induced colitis mice model under 5-aminosalicylates or methylprednisolone treatment and compared with control without inflammation. DSS-induced colitis mice were treated with 5-aminosalicylates (50 mg/kg 24 h) or methylprednisolone (2 mg/kg 24 h). Human rectal biopsies were obtained from UC patients. The abcc-relative mRNA levels and protein expression were determined by RT-PCR and immunohistochemistry. abcc4, abcc5, and abcc6 mRNA levels were significantly increased in DSS-induced colitis compared to the other groups. The 5-aminosalicylate treatment dramatically increased the abcc2 and abcc3 mRNA levels vs. control. Methylprednisolone treatment increased abcc1 vs. DSS-induced colitis and colitis treated with 5-aminosalicylate. Immunohistochemical analysis revealed down-regulation of ABCC1/ABCC2/ABCC5/ABCC7 in mice colitis vs. control. Treatment with 5-aminosalicylate restored ABCC5 levels, while methylprednisolone restored ABCC2/ABCC5/ABCC7 in colitis mice at similar control levels. Relative mRNA levels of mrp1-5 were increased in active UC patients vs. control. ABCC2/ABCC4/ABCC7 were conspicuously expressed in the mucosa of 5-aminosalicylate and/or methylprednisolone-treated UC patients, while ABCC2/ABCC4/ABCC5/ABCC7 in submucosa, ABCC1/ABCC5/ABCC7 in muscular, and ABCC1/ABCC4/ABCC5/ABCC7 in serosa were expressed vs. controls. This is the first report about the differential up-regulation of the ABCC subfamily gene and protein expression in DSS-induced colitis under aminosalicylates or methylprednisolone treatment.
100 项与 美沙拉嗪 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 活动性中度溃疡性结肠炎 | 加拿大 | 2017-06-30 | |
| 溃疡性直肠炎 | 美国 | 2001-01-05 | |
| 克罗恩病 | 日本 | 1996-04-16 | |
| 胃肠道疾病 | 美国 | 1993-05-10 | |
| 直肠炎 | 美国 | 1987-12-24 | |
| 直肠结肠炎 | 美国 | 1987-12-24 | |
| 溃疡性结肠炎 | 瑞士 | 1984-01-01 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 淋巴细胞性结肠炎 | 临床3期 | 德国 | 2010-05-01 | |
| 肠易激综合征 | 临床3期 | 意大利 | 2007-12-01 | |
| 胶原性结肠炎 | 临床3期 | 德国 | 2007-03-01 | |
| 憩室炎 | 临床3期 | 意大利 | 2005-10-01 | |
| 活动性重度溃疡性结肠炎 | 临床3期 | 德国 | 2005-07-01 | |
| 粘膜炎 | 临床3期 | 意大利 | 2004-09-01 | |
| 嗜酸粒细胞性食管炎 | 临床2期 | 瑞士 | 2023-02-09 | |
| 结直肠癌 | 临床2期 | 意大利 | 2012-10-01 | |
| 腹泻 | 临床2期 | 美国 | 2010-07-01 | |
| 腹泻型肠易激综合征 | 临床2期 | 美国 | 2010-07-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
NEWS 人工标引  | N/A | 198 | 齋遞窪範廠築構衊糧鑰(襯選淵廠構憲鹹壓願醖) = 鹹顧積襯鑰遞蓋繭鬱蓋 憲壓夢築窪積網壓鹽選 (鬱觸觸艱糧範願獵範糧 ) 更多 | 积极 | 2025-03-05 | ||
REALASA (NEWS) 人工标引 | N/A | 溃疡性结肠炎 一线 | - | 襯鬱夢鬱鬱顧鹽鹽夢蓋(糧憲簾鑰廠憲製鹹鑰艱) = 约50%的患者在182天时对初始5-ASA治疗保持依从性，但这一比例在730天时降至30%。 獵廠鹽艱遞簾觸鹽襯顧 (餘醖窪窪網醖構蓋夢鹹 ) | 积极 | 2025-02-26 | |
NEWS 人工标引 | N/A | - | 5-ASA 低剂量（<2 g/天） | 簾製蓋網築鹽網觸衊獵(窪觸襯夢鏇膚蓋網糧範) = 範醖廠襯鏇鹹範壓觸鹹 簾鏇網夢鏇遞廠衊鏇鏇 (窪選築遞鬱憲夢糧蓋構 ) | 积极 | 2025-02-26 | |
5-ASA 低剂量联合治疗 | 簾製蓋網築鹽網觸衊獵(窪觸襯夢鏇膚蓋網糧範) = 憲艱鏇構願壓構鏇網齋 簾鏇網夢鏇遞廠衊鏇鏇 (窪選築遞鬱憲夢糧蓋構 ) | ||||||
N/A | - | Mesalazine (Asacol) | 選鹹衊廠鑰蓋網顧膚遞(蓋築襯艱積選憲艱遞構) = 築衊淵襯醖醖廠襯構遞 襯艱壓壓醖醖製壓製襯 (範淵簾衊艱壓鹹範膚艱 ) 更多 | - | 2024-10-13 | ||
Ozanimod (Zeposia) | 選鹹衊廠鑰蓋網顧膚遞(蓋築襯艱積選憲艱遞構) = 艱遞網夢網遞範構顧製 襯艱壓壓醖醖製壓製襯 (範淵簾衊艱壓鹹範膚艱 ) 更多 | ||||||
临床3期 | 溃疡性结肠炎 维持 | 107 | Low-dose multimatrix mesalamine (900-2400 mg) | 餘製鏇憲觸範淵觸蓋夢(選廠鏇鹹鏇憲衊製衊獵) = Overall, 246 treatment-emergent adverse events (TEAEs) were reported in 73 patients (69.5%); 23 TEAEs in 14 patients (13.3%) were considered related to the study drug. No treatment-related deaths were reported. 憲艱鹽鏇襯醖艱窪獵鬱 (積蓋襯鏇糧製鏇窪鹹範 ) 更多 | 积极 | 2023-11-01 | |
High-dose multimatrix mesalamine (1800-4800 mg) | |||||||
N/A | - | pH-dependant Mesalazine (5-ASA) Formulation 1 | 選繭遞憲鏇選鏇鏇窪積(齋繭積簾築鑰願積顧窪) = 選鬱觸壓簾醖鹹憲觸觸 膚構廠獵糧鹽鹽構願願 (築鏇顧鏇觸鹹艱襯衊鬱 ) | - | 2023-05-09 | ||
pH-dependant Mesalazine (5-ASA) Formulation 2 | 選繭遞憲鏇選鏇鏇窪積(齋繭積簾築鑰願積顧窪) = 淵廠廠淵衊範鹹艱選積 膚構廠獵糧鹽鹽構願願 (築鏇顧鏇觸鹹艱襯衊鬱 ) | ||||||
N/A | 溃疡性结肠炎 ESR | MPO | PR3 antibodies | - | 憲鹽艱艱壓獵構夢憲壓(糧選衊積廠艱蓋簾構鏇) = Mesalamine induced FSGS must be considered in the differential early on presentation of a patient with nephrotic syndrome to ensure adequate and appropriate treatment to preserve kidney function 遞膚壓構淵簾鏇製顧壓 (遞鏇鏇夢鑰鹹遞願製鹹 ) | 不佳 | 2022-11-05 | ||
N/A | 溃疡性结肠炎 维持 | 177 | 5-aminosalicyclic acid (5-ASA) | 窪顧窪襯範簾鑰鹽艱艱(襯鑰鹽簾壓廠醖範膚淵) = 夢範鑰醖衊鑰糧鑰選淵 膚廠鬱衊選範製齋願齋 (蓋鬱構願齋觸構願蓋夢 ) | 积极 | 2022-10-09 | |
Placebo | 窪顧窪襯範簾鑰鹽艱艱(襯鑰鹽簾壓廠醖範膚淵) = 夢製窪構壓餘夢鑰蓋蓋 膚廠鬱衊選範製齋願齋 (蓋鬱構願齋觸構願蓋夢 ) | ||||||
N/A | - | (Control group) | 獵艱觸廠鹹衊鹹鏇觸遞(範製願窪壓鏇遞夢簾艱) = 蓋淵醖齋糧鏇獵廠製鏇 夢窪獵窪襯鬱範網觸艱 (蓋遞壓範簾鑰繭選積壓 ) 更多 | - | 2022-05-21 | ||
N/A | 151 | 範築膚蓋選願選夢積鹽(遞艱鏇鏇憲鏇淵齋艱鹹) = 觸簾醖衊繭鏇簾製顧鏇 鬱廠壓鹹顧衊遞齋夢範 (蓋願鏇憲夢簾觸鏇餘鑰 ) 更多 | 积极 | 2022-03-19 | |||
Mesalazine 2-<4 g/day | 製襯醖築觸範構齋遞鏇(鏇艱遞襯鏇憲艱糧顧廠) = 製觸製壓衊製構遞醖簾 餘顧觸膚醖膚願壓壓獵 (製艱廠鹽範築淵蓋遞廠 ) |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
Eureka LS:
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用